+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID07661056

Evaluating BHV-1300 Delivered by Autoinjector Versus Placebo for Treatment of Adult Graves Disease with Active Hyperthyroidism

Led by Biohaven Therapeutics Ltd. · Updated on 2026-10-19

300

Participants Needed

56

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of BHV-1300 in adults with Graves disease who have active hyperthyroidism. This Phase 3, randomized, placebo-controlled study aims to better understand how BHV-1300 may help regulate thyroid function in this population. Participants will be randomly assigned in a 21 ratio to receive either BHV-1300 or a matching placebo. Both treatments are administered by subcutaneous injection using an autoinjector. The study compares these two groups to assess their impact on thyroid hormone levels and antibody status over a 26-week period. During the study, participants will be monitored for thyroid function, antibody levels, and safety outcomes such as adverse events and lab abnormalities. Researchers will measure thyroid hormone levels and antibody changes at various timepoints, with the main focus at Week 26. Participants will also be tracked for their use of antithyroid drugs and overall tolerability of the treatments throughout the study.

CONDITIONS

Brief Title

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

Research Team

C

Chief Medical Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here